Asthma is a complex disease characterized by airway inflammation, bronchial hyper-responsiveness, and airflow obstruction. Tumor necrosis factor-α (TNF), the defining member of the TNF family of cytokines, has been directly implicated in asthmatic airway inflammation and bronchial hyperresponsiveness ([@b5-ehp0115-000616]; [@b64-ehp0115-000616]). Lymphotoxin-α (LTA), also called TNF-β, shares receptors with TNF. The *TNF* \[GenBank accession no. X02910 (<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X02910>)\] and *LTA* \[GenBank accession no. X01393 (<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X01393>)\] genes are located consecutively in the class III region of the human major histocompatibility complex (MHC) on chromosome 6p21, which has shown evidence of linkage to asthma, atopy, and related phenotypes in multiple genome-wide studies ([@b18-ehp0115-000616]; [@b19-ehp0115-000616]).

Single nucleotide polymorphisms (SNPs) of both *TNF* and *LTA* influence gene expression. ([@b35-ehp0115-000616]; [@b36-ehp0115-000616]; [@b45-ehp0115-000616]; [@b52-ehp0115-000616]; [@b73-ehp0115-000616]). In particular, a SNP in the *TNF* promoter region (*TNF*-308) and a SNP within the first intron of *LTA* (*LTA Nco*I) affect the rate of gene transcription and protein production ([@b36-ehp0115-000616]; [@b45-ehp0115-000616]; [@b52-ehp0115-000616]; [@b73-ehp0115-000616]). Several studies have indicated an association of the *TNF*-308 SNP with asthma and atopy susceptibility ([@b2-ehp0115-000616]; [@b9-ehp0115-000616]; [@b15-ehp0115-000616]; [@b22-ehp0115-000616]; [@b25-ehp0115-000616]; [@b28-ehp0115-000616]; [@b40-ehp0115-000616]; [@b39-ehp0115-000616]; [@b47-ehp0115-000616]; [@b58-ehp0115-000616]; [@b59-ehp0115-000616]; [@b60-ehp0115-000616]; [@b69-ehp0115-000616]; [@b74-ehp0115-000616]; [@b75-ehp0115-000616]), although other studies do not ([@b7-ehp0115-000616]; [@b12-ehp0115-000616]; [@b23-ehp0115-000616]; [@b41-ehp0115-000616]; [@b43-ehp0115-000616]; [@b48-ehp0115-000616]; [@b56-ehp0115-000616]; [@b66-ehp0115-000616]; [@b77-ehp0115-000616]). The *LTA Nco*I SNP was reported to be associated with asthma ([@b2-ehp0115-000616]; [@b9-ehp0115-000616]; [@b47-ehp0115-000616]; [@b59-ehp0115-000616]); however, most studies showed no association ([@b12-ehp0115-000616]; [@b13-ehp0115-000616]; [@b23-ehp0115-000616]; [@b30-ehp0115-000616]; [@b31-ehp0115-000616]; [@b40-ehp0115-000616]; [@b41-ehp0115-000616]; [@b46-ehp0115-000616]; [@b48-ehp0115-000616]; [@b50-ehp0115-000616]; [@b56-ehp0115-000616]; [@b58-ehp0115-000616]; [@b60-ehp0115-000616]; [@b66-ehp0115-000616]; [@b68-ehp0115-000616]; [@b69-ehp0115-000616]; [@b75-ehp0115-000616]). The *TNF*-857 and *LTA*-753 SNPs in the promoter regions have also been associated with asthma and atopy ([@b46-ehp0115-000616]; [@b50-ehp0115-000616]). The effects of *TNF* and *LTA* SNPs on asthma and atopy remain unresolved due to the conflicting results across studies.

The etiology of asthma and atopy involves interactions between genetic susceptibility and exposure to environmental triggers, such as secondhand smoke, ozone, particulate matter, allergens, and endotoxin ([@b63-ehp0115-000616]). *TNF* has been identified as a candidate gene for ozone-induced airway inflammation and hyperresponsiveness ([@b34-ehp0115-000616]), and genetic variation in *TNF* and *LTA* has been associated with respiratory effects of ozone in humans ([@b76-ehp0115-000616]). Parental smoking has been consistently related to childhood asthma \[U.S. [@b21-ehp0115-000616]\] and TNF may influence the lung inflammatory response to tobacco smoke ([@b16-ehp0115-000616]; [@b54-ehp0115-000616]). Few studies have examined whether exposure to parental smoking modifies the relationship between *TNF* and *LTA* polymorphisms and asthma risk. We used the case--parent triad design to investigate the association of *TNF* and *LTA* polymorphisms and haplotypes with childhood asthma and atopy in asthmatic children from Mexico City, an area with the highest ozone exposure in North America. We also examined possible effect modification by exposure to parental smoking.

Methods
=======

Study design and subject enrollment
-----------------------------------

We used the case--parent triad design ([@b70-ehp0115-000616]; [@b72-ehp0115-000616]). The study population included 536 case--parent triads and 60 case--parent pairs with adequate DNA samples for genotyping of at least one SNP for the *TNF* and *LTA* genes. The cases were children 4--17 years of age with asthma diagnosed by a pediatric allergist at the allergy referral clinic of a large public pediatric hospital in central Mexico City (Hospital Infantil de Mexico Federico Gomez). Children and parents provided blood samples as sources of DNA. A parent, nearly always the mother, completed a questionnaire on the child's symptoms and risk factors for asthma including current parental smoking, parental smoking during the first 2 years of the child's life, maternal smoking during pregnancy, and residential history.

We obtained measurements of ambient ozone from the Mexican government's air monitoring stations (<http://www.ine.gob.mx/dgicurg/calaire/tend/concentra.php>). Ozone levels were measured via ultraviolet photometry (analyzer model 400, Advanced Pollution Instrumentation, San Diego, CA, USA). The residence of each child who participated in this study was located using a map, and the closest monitoring station was assigned to that residence ([@b57-ehp0115-000616]). The ozone exposure data were collected for the year before the time of entry into the study. The parameter we used was the annual average of the daily maximum 8-hr averages. We dichotomized this variable at the median of 67 ppb for stratified analyses.

The protocol was reviewed and approved by the institutional review boards of the Mexican National Institute of Public Health, the Hospital Infantil de Mexico Federico Gomez, and the U.S. National Institute of Environmental Health Sciences (NIEHS). Parents provided the written informed consent for the child's participation. Children also gave their informed assent.

Clinical evaluation
-------------------

The diagnosis of asthma was based on clinical symptoms and response to treatment by a pediatric allergist \[[@b11-ehp0115-000616]\]. The severity of asthma was rated by a pediatric allergist for 571 cases according to symptoms in the Global Initiative on Asthma schema as mild (intermittent or persistent), moderate, or severe \[[@b49-ehp0115-000616]\]. At a different point of time, for research purposes, pulmonary function was measured using the EasyOne spirometer (ndd Medical Technologies, Andover, MA, USA) for 446 cases according to American Thoracic Society (ATS) specifications ([@b4-ehp0115-000616]). The best test of three technically acceptable tests was selected. Spirometric prediction equations from a Mexico City childhood population were used to calculate the percent predicted forced expiratory volume in 1 sec (FEV~1~) ([@b55-ehp0115-000616]). Children were asked to hold asthma medications on the morning of the test.

Atopy was determined using skin prick tests. The following battery of 24 aeroallergens common in Mexico City was used: *Aspergillus fumigatus*, *Alternaria*, *Mucor*, *Blattella germanica*, *Periplaneta americana*, *Penicillium*, cat, dog, horse, *Dermatophagoides (pteronyssinus and farina)*, *Ambrosia*, *Artemisa ludoviciana*, *Cynodon dactylon*, *Chenopodium album*, *Quercus*, *Fraxinus*, *Helianthus*, *Ligustrum vulgare*, *Lolium perenne*, *Plantago lanceolata*, *Rumex crispus*, *Schinus molle*, *Salsola*, and *Phleum pratense*. Histamine was used as a positive control and glycerin as a negative control. Children were considered atopic if the diameter of the skin reaction to at least one allergen exceeded 4 mm. The test was considered valid if the reaction to histamine was ≥ 6 mm according to the grading of skin prick test recommended by [@b1-ehp0115-000616]. Skin test data on all 24 aeroallergens were available on 545 cases.

SNP selection
-------------

We had various data sources available for selection of tagging SNPs. These included resequencing data in individuals of African and European descent by Seattle SNPs (<http://pga.mbt.washington.edu>) and genotyping data on 10 Mexicans and 38 Mexican-Americans with four grandparents born in Mexico for cosmopolitan haplotype tagging SNPs identified by the NIEHS Environmental Genome Project based on resequencing a representative sample of the U.S. population (<http://egp.gs.washington.edu>). We identified the common haplotypes using PHASE ([@b61-ehp0115-000616]) and then used ldSelect ([@b14-ehp0115-000616]) to identify tagging SNPs. We also analyzed the genotyping data from seven Mexicans in SNP500Cancer ([@b53-ehp0115-000616]) (<http://snp500cancer.nci.nih.gov>). *TNF* and *LTA* are small genes located consecutively in a 6 kb region on chromosome 6, and linkage disequilibrium in this region is high. We selected six tagging SNPs---*TNF*-1031 (rs1799964), *TNF*-857 (rs1799724), *TNF*-308 (rs1800629), *TNF*-238 (rs361525), *LTA*-379 (rs2239704), and *LTA NcoI* (rs909253)---to cover the whole region, including all the common SNPs in the regulatory and coding regions of the genes with known functional importance ([@b24-ehp0115-000616]; [@b35-ehp0115-000616]; [@b36-ehp0115-000616]; [@b45-ehp0115-000616]; [@b52-ehp0115-000616]; [@b73-ehp0115-000616]) or that had been associated with asthma in the literature. As expected, given the increasing documentation of the portability of tagging SNPs across populations ([@b27-ehp0115-000616]), especially in the less diverse non-African groups, the tagging SNPs selected provide excellent coverage of common haplotypes in other populations. For example, the six tagging SNPs we selected based on the Mexican data would cover all six common haplotypes (\> 5%) in European and five of six common haplotypes in African populations.

Genotyping
----------

We extracted DNA from peripheral blood lymphocyte using Gentra Puregene kits (Gentra System, Minneapolis, MN, USA). We obtained genotypes for the *TNF*-1031 and *TNF*-857 SNPs using TaqMan SNP Genotyping Assay ([@b39-ehp0115-000616]). Primers and probes were purchased from Assay-on-Demand (Applied Biosystems, Foster City, CA, USA). All PCR amplifications were performed using 5′ exonuclease assay on GeneAmp PCR Systems 9700 (Applied Biosystems). The fluorescence of PCR products was detected using ABI Prism 7900HT sequence detection system. The *TNF*-308, *TNF*-238, and *LTA Nco*I SNPs were genotyped using a multiplex PCR and immobilized probe linear array system ([@b6-ehp0115-000616]), provided by Roche Molecular Systems (Alameda, CA, USA). The *LTA*-379 SNP was genotyped using MGB Eclipse Genotyping Assay ([@b8-ehp0115-000616]). Primers and Probes were purchased from MGB Eclipse by Design (Epoch Biosciences, Bothell, WA, USA). All genotyping assays were done by a researcher who was blinded to parent or child status of samples. Sixteen quality control samples were plated per 384-well plate along with 24 control samples with known genotype. An additional six blind replicate samples were included in the analyses. The quality controls and the blind replicates were 100% concordant for all genotyping methods.

Nonparentage was ascertained with a set of short-tandem repeats (AmpFLSTR Profiler Plus; Applied Biosystems) analyzed using Pedcheck software (University of Pittsburgh, Pittsburgh, PA, USA) ([@b51-ehp0115-000616]). A total of 596 families had genotyping data for at least one SNP, and 566 families had genotyping data for all six SNPs.

Statistical analysis
--------------------

We used a log-linear likelihood approach to analyze associations between asthma and individual SNPs ([@b70-ehp0115-000616]). The log-linear likelihood-ratio test is a powerful and more flexible alternative to the transmission disequilibrium test (TDT) and tests the same null hypothesis of no within-family relationship between the variant and the disease ([@b37-ehp0115-000616]). Similar to TDT-based methods for the analysis of case--parent data, such as the family-based association test (FBAT) ([@b29-ehp0115-000616]), the log-linear model achieves robustness against genetic population structure through stratification on the possible parental mating types ([@b37-ehp0115-000616]). The log-linear method has the advantage of providing estimates of the magnitude of associations rather than simply tests of significance ([@b70-ehp0115-000616]). We calculated relative risks for individual SNPs without restricting to a specific genetic model. The log-linear models of case--parent data are inherently immune to confounding by demographic or lifestyle factors such as parental smoking. However, we examined effect modification by sex, asthma severity, parental smoking, and level of ozone exposure. We calculated tests of interactions for the joint effects of genotype and current parental smoking and parental smoking before the child turned two using the method of [@b67-ehp0115-000616]. All analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) and STATA version 8.0 (StataCorp., College Station, TX, USA).

To evaluate whether *TNF* and *LTA* polymorphisms influenced the degree of atopy, as assessed by the number of positive skin tests out of 24 performed, we used the polytomous logistic method of Kistner and Weinberg to estimate the linkage and association between *TNF* and *LTA* polymorphisms and atopy ([@b33-ehp0115-000616]). *p*-Values were calculated from likelihood ratio tests. We also used this method to analyze the relationship between *TNF* and *LTA* SNPs and lung function, as assessed by percent predicted FEV~1~.

We used HAPLIN version 2.0 (<http://www.uib.no/smis/gjessing/genetics/software/haplin>) to analyze associations between asthma and *TNF* and *LTA* haplotypes. HAPLIN is an extension of the log-linear model from a single locus to loci with multiple haplotypes with unknown phase ([@b26-ehp0115-000616]). The haplotypes of individuals with unknown phase are constructed from the family information whenever possible, and the remaining haplotypes are estimated by using the expectation-maximization algorithm ([@b26-ehp0115-000616]). HAPLIN estimates single- and double-dose effects of haplotypes rather than simply tests of significance using maximum likelihood ([@b26-ehp0115-000616]). We set a threshold of 1% for haplotype frequency, leaving 582 families in the HAPLIN analyses.

We present the *p*-values computed using the above methods. To address the potential issue of multiple comparisons, we calculated the false discovery rate for each *p*-value \< 0.05 using the method of Storey ([@b62-ehp0115-000616]). The false discovery rate is the expected proportion of false positives incurred when a particular test is called significant. However, these corrections will be overly conservative when applied equally to all SNPs. Our prior prediction of positive findings would be greatest for SNPs with known functional importance, such as *TNF*-308, compared with SNPs chosen only as haplotype tagging SNPs where functional significance is not well characterized. In addition, the false discovery rate does not take into account the correlation between SNPs in a gene.

Results
=======

Clinical characteristics of the asthmatic children with genotyping data are presented in [Table 1](#t1-ehp0115-000616){ref-type="table"}. The mean (± SD) age of cases was 9.0 ± 2.4 years (range 4--17 years). Most had mild (71.5%) as opposed to moderate or severe asthma (28.5%). Nearly all cases (98.3%) had used medication for asthma in the preceding 12 months. Wheezing in the preceding 12 months was reported by 89.8% and chronic dry cough was reported by 65.4%. For 73.9% of cases, asthma symptoms had interfered with daily activities or school attendance in the preceding 12 months. Among cases with spirometry data, the mean FEV~1~ percent predicted was 96.7 ± 20.6. Atopy was present in 91.9% of cases. The highest rates of skin test positivity were seen for dust mite (70.3%) and cockroach (43.1%). Although only 5.8% of mothers reported smoking during pregnancy, 32.6% of cases lived with a smoking parent in early childhood (before 2 years of age) and 50.4% were currently exposed to parental smoking.

The minor allele frequency and genotype frequency distributions of the six tagging SNPs are shown in [Table 2](#t2-ehp0115-000616){ref-type="table"}. The *TNF*-308 and *TNF*-238 polymorphisms were relatively rare in our Mexican population (minor allele frequency = 5% for *TNF*-308 and 4% for *TNF*-238). The frequency distributions for all mating types for *TNF* and *LTA* polymorphisms are presented in Supplemental [Table 1](#t1-ehp0115-000616){ref-type="table"} for all families, Supplemental [Table 2](#t2-ehp0115-000616){ref-type="table"} for families with smoking parents, and Supplemental [Table 3](#t3-ehp0115-000616){ref-type="table"} for families with non-smoking parents (Supplemental Material online at <http://www.ehponline.org/docs/2007/9740/suppl.pdf>). Hardy-Weinberg equilibrium (*p* \> 0.1) was confirmed for all six tagging SNPs in the parents. Pairwise linkage disequilibrium coefficients, *D*, and *r* ^2^, between *LTA* and *TNF* SNPs, calculated using FBAT ([@b29-ehp0115-000616]) are shown in Supplemental [Table 4](#t4-ehp0115-000616){ref-type="table"} in the online Supplemental Material. There was moderate linkage disequilibrium between the *LTA*-379 and *LTA Nco*I polymorphisms (*r* ^2^ = 0.50), and weak linkage disequilibrium between the *LTA*-379 and *TNF*-857 polymorphisms (*r* ^2^ = 0.39), the *TNF*-1031 and *TNF*-238 polymorphisms (*r* ^2^ = 0.25), the *LTA Nco*I and *TNF*-857 polymorphisms (*r* ^2^ = 0.20), and the *LTA*-379 and *TNF*-1031 polymorphisms (*r*^2^ = 0.16). The *r*^2^ values for all other SNP pairs were \< 0.1.

Neither of the two SNPs in *LTA* was associated with asthma ([Table 3](#t3-ehp0115-000616){ref-type="table"}). For *TNF*, carrying at least one copy of the *TNF*-308A allele was associated with increased asthma risk \[relative risk (RR) = 1.54; 95% confidence interval (CI), 1.04--2.28; *p* = 0.031; false discovery rate = 0.12\] relative to homozygotes for the major G allele ([Table 3](#t3-ehp0115-000616){ref-type="table"}). Only three cases were homozygous for the minor allele for *TNF*-238 and none for *TNF*-308, so we were not able to evaluate the relative risks for homozygotes. The *TNF*-238, *TNF*-857, and *TNF*-1031 polymorphisms gave weaker, and more unstable, evidence of association with asthma ([Table 3](#t3-ehp0115-000616){ref-type="table"}). Results for the six tagging SNPs did not differ appreciably by sex, asthma severity (mild versus moderate to severe), or ozone level (data not shown). We did not observe a clear pattern of associations between the *TNF* and *LTA* SNPs and percent predicted FEV~1~ (data not shown).

Because of the consistent association between parental smoking and childhood asthma ([@b21-ehp0115-000616]) and the involvement of TNF in cigarette smoke--induced inflammation responses ([@b16-ehp0115-000616]; [@b54-ehp0115-000616]), we examined the association of each *LTA* and *TNF* SNP with asthma stratified by exposure to a smoking parent in the home. Among cases without smoking parents in the home, the *TNF*-308A allele and *TNF*-238A alleles showed increased risk of asthma (RR = 2.06; 95% CI, 1.19--3.55; *p* = 0.0097; false discovery rate = 0.04 for *TNF*-308A; RR = 2.21; 95% CI, 1.14--4.30; *p* = 0.019; false discovery rate = 0.04 for *TNF*-238A) ([Table 3](#t3-ehp0115-000616){ref-type="table"}). The *p*-values for interaction with living with smoking parents were 0.09 for *TNF*-308 and 0.01 for *TNF*-238. For the other two *TNF* SNPs, although the results were not statistically significant, the increased risk of asthma for carrying two copies of the minor allele also appeared to be limited to cases with nonsmoking parents (RR = 2.36; 95% CI, 0.82--6.78 for *TNF*-1031C; RR = 1.32; 95% CI, 0.76--2.29 for *TNF*-857T). Among cases with smoking parents in the home, none of the six *LTA* and *TNF* polymorphisms were associated with asthma ([Table 3](#t3-ehp0115-000616){ref-type="table"}).

Haplotype analyses results reflected the single SNP findings in magnitude and direction ([Table 4](#t4-ehp0115-000616){ref-type="table"}). Among all cases, individuals carrying one copy of the ht5 (CGTCAG) haplotype, containing the *TNF*-308A allele, exhibited an increased risk of asthma of borderline statistical significance (RR = 1.45; 95% CI, 0.97--2.19). Among cases with non-smoking parents, carrying one copy of the ht6 (CACCGA) haplotype containing the *TNF*-238A allele or one copy of the ht5 haplotype exhibited an increased risk of asthma (RR = 2.15; 95% CI, 1.21--3.82; *p* = 0.0082 for ht5; RR = 2.40; 95% CI, 1.18--4.81; *p* = 0.014 for ht6). The false discovery rate was 0.03 for the ht5 and ht6 findings. Among cases with smoking parents, *LTA* and *TNF* haplotypes were not associated with asthma ([Table 4](#t4-ehp0115-000616){ref-type="table"}).

We also examined the association of *LTA* and *TNF* individual SNPs and haplotypes with asthma stratified by exposure to a smoking parent before child turned two because exposure in early childhood has also been consistently associated with childhood asthma risk ([@b21-ehp0115-000616]). The analysis results were consistent with findings for stratifying by current exposure to a smoking parent in the home (data not shown).

We examined the association between individual *LTA* and *TNF* SNPs and the degree of atopy to aeroallergens, assessed by the number of positive skin tests out of a battery of 24 tests. No significant associations were detected with the number of positive skin tests for the six *LTA* and *TNF* SNPs (data not shown).

Discussion
==========

In this case--parent triad study in a Mexico City population with high lifetime exposure to ozone, we found that the A allele of the functionally relevant *TNF*-308 polymorphism was significantly associated with an increased risk of childhood asthma, especially among children with nonsmoking parents. The *TNF*-238A allele and the haplotypes containing the *TNF*-308A allele or the *TNF*-238A allele were associated with an increased childhood asthma risk predominantly in children with nonsmoking parents.

TNF is a potent proinflammation cytokine and has been consistently implicated in asthmatic inflammation and bronchial hyperresponsiveness in a variety of subcellular, *in vitro*, *ex vivo*, *in vivo*, and genetic studies ([@b64-ehp0115-000616]). For example, TNF expression is markedly increased in asthmatic airways compared with normal airways ([@b10-ehp0115-000616]). TNF appears to have an important amplifying effect on asthmatic inflammation ([@b5-ehp0115-000616]) and has also been shown to induce airway hyperresponsiveness in rats and humans ([@b32-ehp0115-000616]; [@b65-ehp0115-000616]). Therefore, genetic polymorphisms that affect gene expression or TNF activity in the airways might be expected to influence asthma risk.

The *TNF*-308 polymorphism has been frequently studied in asthma and atopy association studies because it has direct functional effects on *TNF* gene regulation. The *TNF*-308A allele is a much stronger transcriptional activator than the more common G allele ([@b73-ehp0115-000616]) and is associated with higher TNF production ([@b42-ehp0115-000616]). The *TNF*-308A allele leads to high binding affinity of nuclear factors to the *TNF* promoter and gives a high level of gene transcription ([@b36-ehp0115-000616]). Thus, observations from functional studies suggest that the *TNF*-308A allele is of biological significance. Despite the known effects of tobacco smoke on TNF expression and the well-documented association between parental smoking and childhood asthma, few studies have evaluated whether exposure to a smoking parent modifies effects of genetic variation in *TNF* on childhood asthma. In our study, the association was greater among children without smoking parents in the home.

We also found an association between the *TNF*-238A allele and asthma risk among children with nonsmoking parents in the home. The *TNF*-238 polymorphism was not in linkage disequilibrium with the *TNF*-308 polymorphism (*r*^2^ \< 0.01) in our Mexican population, although they are only 70 bp apart from each other within the class III region of the MHC on chromosome 6p. There is no strong evidence showing that the *TNF*-238 polymorphism has a direct effect on gene expression, although studies suggest that this region contains a strong repressor site (−280 to −172) ([@b24-ehp0115-000616]). However, the *TNF*-238 polymorphism may be in linkage disequilibrium with a functional polymorphism that impacts TNF production, either within the *TNF* gene or another gene within the MHC.

Because the etiology of asthma involves numerous environmental triggers, heterogeneous exposure to environmental stimuli among different populations may cause conflicting results across studies. The influence of genotypes on phenotypes may be different and even opposite at different levels of exposure ([@b44-ehp0115-000616]). Therefore, incorporating environmental exposures, such as parental smoking, into association studies is important. Parental smoking, a reasonably valid approach to estimate long-term secondhand smoke exposure in infants and children, is one of the most consistent risk factors for childhood asthma ([@b21-ehp0115-000616]).

It is not unexpected to find differing associations between genetic polymorphisms and asthma susceptibility based on parental smoking exposure. We previously reported that the protective effect for the NQO1 Ser allele in GSTM1-null children was limited to those with nonsmoking parents ([@b20-ehp0115-000616]). A recent genome-wide linkage study found different regions of linkage to childhood asthma by parental smoking exposure ([@b17-ehp0115-000616]). Of note, the chromosome 6p region, containing the *TNF* gene, was more strongly linked to asthma among subjects who did not live with a smoker during infancy compared with those who lived with smokers ([@b17-ehp0115-000616]).

A recent study showed that the *TNF*-308 polymorphism modified the effect of home exposure to smokers on respiratory illness-related school absence among children mostly without asthma ([@b71-ehp0115-000616]). Another study in the same population showed that the *TNF*-308A allele was associated with an increased risk of wheezing, especially among children living in low ozone communities ([@b39-ehp0115-000616]). In the present study, we found that *TNF* polymorphisms and haplotypes were associated with childhood asthma susceptibility predominantly among children who did not live with smoking parents.

Because *TNF* is a candidate gene for ozone-induced airway inflammation and hyperresponsiveness ([@b34-ehp0115-000616]), we stratified on the ozone level. It is not surprising that we did not observe effect modification by ozone because our population in central Mexico City was exposed to high lifetime levels of ozone compared with U.S. populations. The median level of the annual average of the daily maximum 8-hr averages for our population was 67 ppb, with an interquartile range of only 12 ppb.

A possible explanation for our finding of an association of *TNF* polymorphisms with asthma predominantly for children without smoking parents is that the combination of exposure to secondhand smoke and ozone, which both increase TNF production, overwhelms the smaller impact of *TNF* polymorphisms on TNF expression. Indeed, expression levels of TNF are significantly increased in mice and humans exposed to tobacco smoke ([@b16-ehp0115-000616]; [@b54-ehp0115-000616]). TNF has been identified as a potential candidate gene for ozone susceptibility ([@b34-ehp0115-000616]; [@b76-ehp0115-000616]) and ozone exposure can stimulate TNF secretion from lung cells ([@b3-ehp0115-000616]). Tobacco smoke and ozone are both strong oxidants ([@b63-ehp0115-000616]) and potent controllers of TNF production ([@b3-ehp0115-000616]; [@b16-ehp0115-000616]; [@b54-ehp0115-000616]). In combination, these environmental triggers may have synergistic effects and overcome the smaller effects of *TNF* polymorphisms. Conversely, in the absence of secondhand smoke exposure, the influence of *TNF* functional polymorphisms on TNF expression may be greater, which could explain our finding of stronger associations at lower levels of exposure. Of note, for CD14, a pattern recognition receptor in the endotoxin-induced immune response, associations between the *CD14*-159 polymorphism and asthma and atopy differ at high versus low levels of endotoxin exposure ([@b44-ehp0115-000616]).

In summary, we found that *TNF* polymorphisms and haplotypes were associated with childhood asthma susceptibility, especially among children without smoking parents. These results suggest that the effects of genetic variation in *TNF* may be more apparent at lower levels of exposure to substances such as secondhand smoke, which strongly influence TNF expression.

Supplemental Material is available online at <http://www.ehponline.org/docs/2007/9740/suppl.pdf>
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###### 

Demographic and clinical characteristics of the 596 asthmatic children.

  Clinical characteristics                                   Value
  ---------------------------------------------------------- -------------
  Age \[years (mean ± SD)\]                                  9.0 ± 2.4
  Sex (male)                                                 61.1
  Asthma severity (*n* = 571)                                
   Mild                                                      71.5
   Moderate to severe                                        28.5
  Asthma medication in the preceding 12 months (*n* = 590)   98.3
  FEV~1~ \[percent predicted (mean ± SD)\] (*n* = 446)       96.7 ± 20.6
  Skin test positivity (of 24 aeroallergens) (*n* = 545)     
   ≥ 1 allergen                                              91.9
   ≥ 5 allergens                                             52.8
  Parental smoking (*n* = 591)                               
   Mother smoked during pregnancy                            5.8
   In early childhood (\< 2 years of age)                    32.6
   Current smoking parent                                    50.4

Values are expressed as percent except where noted.

###### 

Genotype distributions for *LTA* and *TNF* polymorphisms.

  Locus        Genotype   All cases   No. of cases with smoking parents   No. of cases with nonsmoking parents   Minor allele frequency[a](#tfn3-ehp0115-000616){ref-type="table-fn"}
  ------------ ---------- ----------- ----------------------------------- -------------------------------------- ----------------------------------------------------------------------
  *LTA*-379    CC         159         85                                  74                                     0.48
               CA         299         147                                 148                                    
               AA         138         66                                  71                                     
  *LTA Nco*I   AA         251         121                                 128                                    0.34
               AG         268         141                                 124                                    
               GG         65          32                                  33                                     
  *TNF*-1031   TT         420         208                                 208                                    0.15
               TC         146         74                                  71                                     
               CC         18          9                                   9                                      
  *TNF*-857    CC         316         165                                 150                                    0.27
               CT         221         106                                 111                                    
               TT         50          21                                  29                                     
  *TNF*-308    GG         513         268                                 240                                    0.05
               GA         65          25                                  40                                     
               AA         0           0                                   0                                      
  *TNF*-238    GG         525         269                                 252                                    0.04
               GA         50          22                                  28                                     
               AA         3           2                                   1                                      

See the Supplemental Material (<http://www.ehponline.org/docs/2007/9740/suppl.pdf>) for the frequency distributions for all mating types for *TNF* and *LTA* polymorphisms for all families and by parental smoking status.

Minor allele frequency was calculated using parent genotyping data.

###### 

*LTA* and *TNF* polymorphisms in relation to childhood asthma risk among all cases and stratified by parental smoking status \[RR (95% CI)\].

  Locus        Genotype                                           All cases                                                          Cases with smoking parents   Cases with nonsmoking parents
  ------------ -------------------------------------------------- ------------------------------------------------------------------ ---------------------------- --------------------------------------------------------------------
  *LTA*-379    CC                                                 1.0                                                                1.0                          1.0
               CA                                                 1.04 (0.82--1.32)                                                  0.95 (0.68--1.31)            1.11 (0.78--1.57)
               AA                                                 0.98 (0.71--1.34)                                                  0.93 (0.59--1.45)            1.02 (0.65--1.62)
  *LTA Nco*I   AA                                                 1.0                                                                1.0                          1.0
               AG                                                 1.00 (0.80--1.24)                                                  1.04 (0.76--1.43)            0.94 (0.68--1.30)
               GG                                                 0.89 (0.61--1.29)                                                  1.00 (0.60--1.69)            0.79 (0.46--1.35)
  *TNF*-1031   TT                                                 1.0                                                                1.0                          1.0
               TC                                                 1.01 (0.78--1.30)                                                  0.89 (0.61--1.30)            1.14 (0.80--1.64)
               CC                                                 1.22 (0.64--2.33)                                                  0.87 (0.38--2.00)            2.36 (0.82--6.78)
  *TNF*-857    CC                                                 1.0                                                                1.0                          1.0
               CT                                                 0.96 (0.77--1.19)                                                  0.88 (0.64--1.20)            0.99 (0.73--1.35)
               TT                                                 1.13 (0.75--1.70)                                                  0.93 (0.51--1.71)            1.32 (0.76--2.29)
  *TNF*-308    GG                                                 1.0                                                                1.0                          1.0
               GA                                                 1.54 (1.04--2.28)[\*](#tfn5-ehp0115-000616){ref-type="table-fn"}   1.09 (0.61--1.94)            2.06 (1.19--3.55)[\*\*](#tfn6-ehp0115-000616){ref-type="table-fn"}
               AA[a](#tfn4-ehp0115-000616){ref-type="table-fn"}   ---                                                                ---                          ---
  *TNF*-238    GG                                                 1.0                                                                1.0                          1.0
               GA                                                 1.22 (0.81--1.85)                                                  0.81 (0.46--1.42)            2.21 (1.14--4.30)[\#](#tfn7-ehp0115-000616){ref-type="table-fn"}
               AA[a](#tfn4-ehp0115-000616){ref-type="table-fn"}   ---                                                                ---                          ---

Only three cases were homozygous for the minor A allele for *TNF*-238 and none for *TNF*-308, so we did not calculate those relative risks.

*p* = 0.031; false discovery rate = 0.12.

*p* = 0.0097; false discovery rate = 0.04; *p*-value for interaction = 0.09.

*p* = 0.019; false discovery rate = 0.04; *p*-value for interaction = 0.01.

###### 

*TNF* and *LTA* haplotypes in relation to childhood asthma risk among all cases and stratified by parental smoking status \[RR (95% CI)\].

  Haplotype[a](#tfn8-ehp0115-000616){ref-type="table-fn"}   Frequency   Single copy                                                           Double copy
  --------------------------------------------------------- ----------- --------------------------------------------------------------------- ---------------------------------------------------
  All cases                                                                                                                                   
   ht1 (CGTCGG)                                             0.305       0.94 (0.75--1.18)                                                     0.80 (0.53--1.21)
   ht2 (AATTGG)                                             0.271       0.92 (0.72--1.15)                                                     1.11 (0.73--1.67)
   ht3 (AATCGG)                                             0.208       1.00 (0.79--1.26)                                                     1.00 (0.60--1.66)
   ht4 (CACCGG)                                             0.112       0.87 (0.65--1.16)                                                     1.04 (0.47--2.33)
   ht5 (CGTCAG)                                             0.040       1.45 (0.97--2.19)                                                     ---[b](#tfn9-ehp0115-000616){ref-type="table-fn"}
   ht6 (CACCGA)                                             0.035       1.31 (0.85--2.03)                                                     ---
   ht7 (CATCGG)                                             0.027       1.03 (0.62--1.73)                                                     ---
  Cases with smoking parents                                                                                                                  
   ht1 (CGTCGG)                                             0.298       1.18 (0.86--1.63)                                                     1.02 (0.57--1.81)
   ht2 (AATTGG)                                             0.271       0.86 (0.62--1.21)                                                     0.89 (0.49--1.66)
   ht3 (AATCGG)                                             0.198       1.09 (0.78--1.54)                                                     1.30 (0.65--2.63)
   ht4 (CACCGG)                                             0.117       0.88 (0.58--1.31)                                                     0.98 (0.32--3.03)
   ht5 (CGTCAG)                                             0.042       0.90 (0.49--1.67)                                                     ---
   ht6 (CACCGA)                                             0.047       0.84 (0.46--1.52)                                                     ---
   ht7 (CATCGG)                                             0.022       1.50 (0.72--3.15)                                                     ---
  Cases with nonsmoking parents                                                                                                               
   ht1 (CGTCGG)                                             0.310       0.74 (0.54--1.02)                                                     0.64 (0.36--1.16)
   ht2 (AATTGG)                                             0.274       0.92 (0.66--1.27)                                                     1.29 (0.72--2.22)
   ht3 (AATCGG)                                             0.212       0.94 (0.66--1.31)                                                     0.81 (0.38--1.73)
   ht4 (CACCGG)                                             0.107       0.86 (0.57--1.31)                                                     1.16 (0.37--3.53)
   ht5 (CGTCAG)                                             0.038       2.15 (1.21--3.82)[\*](#tfn10-ehp0115-000616){ref-type="table-fn"}     ---
   ht6 (CACCGA)                                             0.022       2.40 (1.18--4.81)[\*\*](#tfn11-ehp0115-000616){ref-type="table-fn"}   ---
   ht7 (CATCGG)                                             0.032       0.71 (0.34--1.49)                                                     ---

The haplotypes formed by *LTA*-379C \> A, *LTA Nco*IA \> G, *TNF*-1031T \> C, *TNF*-857C \> T, *TNF*-308G \> A, and *TNF*-238G \> A in order.

Only three cases were homozygous for the ht6 haplotype and none for the ht5 and ht7 haplotypes, so we did not calculate those relative risks.

*p* = 0.0082; false discovery rate = 0.03.

*p* = 0.014; false discovery rate = 0.03.

[^1]: L.L.S. is employed by Roche Molecular Systems; genotyping reagents for some analyses were provided by Roche Molecular Systems at no cost under a research collaboration agreement. The authors declare they have no competing financial interests.
